Seroconversion rates following 2 doses of measles- mumps- rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age

Hana Saffar1, Sayed Jaber Mousavi2, Hiva Saffar3, Mohammad-Reza Parsaei4, Gholam-Reza Ghorbani4 and Mohammad Jafar Saffar5*

Abstract

Background: Despite high rate of vaccination coverage with 2-doses of measles containing vaccine among Iranian children, outbreaks of measles occurred among different age groups and fully vaccinated subjects. Although the main reason for these outbreaks is unknown, however, vaccine failure was supposed to be an important cause. This study was designed to determine the seroconversion rates to measles- mumps- rubella (MMR) vaccine currently in use among Iranian children.

Methods: This prospective study was conducted among healthy children older than 12 months who were candidates of scheduled MMR vaccination. Blood samples were obtained from each mother-infant pair just before vaccination, and from infants 4–6 weeks after MMR1 and MMR2 immunization. Collected sera were tested for specific IgG antibodies against MMR agents using ELISA method. The proportion of seroprotected subjects among mother-infant pairs before vaccination as well as the prevalence rates of seroconversion after MMR1 and MMR2 vaccination were calculated. Collected data were analyzed using descriptive statistical methods.

Results: During 22-months study period, 92 mother-infant pairs were participated. Seroimmunity rates against MMR viruses were 85.8%, 84.7% and 86.9% for mothers, and 3.2%, 2.1% and 1.0% for children, respectively. After MMR1 vaccination from 52 seronegative children, 80.7%, 78.8% and 75% were seroconverted. These rates increased to 94.8%, 89.7% and 94.8% after the MMR2 vaccination. Also, the specific immunity was enhanced among seropositive children.

Conclusion: Majority of the mothers and few infants were immune to MMR viruses prior to MMR1 vaccination. Immune responses detected after MMR1 injection, and overall seroconversion rates achieved after 2-doses of MMR vaccination were less than expected and inadequate to preserve long-term protection against MMR agents.

Keywords: Seroconversion rate, MMR, Iran, Measles, Mumps, Rubella, Elimination, Primary vaccine failure

Background

Measles, mumps, and rubella (MMR) are communicable viral illnesses that are preventable through vaccination. Measles is a highly contagious infection that can be transmitted to more than 90% of susceptible subjects and is still a major cause of death among children, particularly in children less than 5 years old [1]. About 140,000
measles deaths were reported worldwide in 2018 [2]. From first of January to the end of July of 2019, more than 364,806 cases of measles were reported from 182 countries in the world; this rate surpassed 23% from the similar period in 2018 [2, 3]. Mumps, an acute contagious disease, most often affects susceptible children to young adults in the closed crowded community and can be associated with serious complications such as: meningoencephalitis, orchitis, pancreatitis, myocarditis, and nephritis [4, 5]. Rubella, a mild exanthematous illness, can be a real threat when infecting pregnant women especially in the first trimester and can result in fetal loss or devastating multiple anomalies known as congenital rubella syndrome (CRS) [6, 7].

According to the World Health Organization (WHO) and other authorities, all children should receive a second dose of MMR vaccine with the aim of reduction in proportion of primary vaccine failure (PVF) in susceptible individuals and also this act as an essential strategic key measure of measles elimination [1, 8–11].

Following universal two doses scheduled monovalent measles vaccine (mMV) immunization of the Iranian children from 1984, and the national measles—rubella (MR) campaign of the 5–25 year-old population in December 2003, the incidence of measles cases in the Iran reduced markedly [12, 13]. However, despite the high vaccine coverage rates, during recent years small outbreaks of measles have occurred even among fully vaccinated subjects in some regions of the country. The true reasons for these outbreaks are not clear. However, for more description, a brief epidemiological characteristics of reported measles outbreaks from the year 2006 are presented in Table 1 [14–18].

Previous measles seroprevalence studies conducted in the Iran showed a gap between immunization coverage rates and the proportion of those who were seropositive [19]. The extent of this gap is influenced by several factors including age at the time of initial immunization and time elapsed since the last vaccination [20–22], as well as vaccine related factors such as: type of the virus strain and cold-chain regulation in health care centers [23]. In order to determine the immunogenicity of MMR vaccine among Iranian children, some studies were performed. The seroconversion rates against MMR agents observed in these studies varied markedly [24–27]. While in one study from Ahwaz, 6 months following scheduled MMR vaccination of older than 12 month-old children, the detected seroconversion rates were 42.9%, 58.6% and 90%, against MMR agents [24], in another similar study from Tehran, these rates were 75.8%, 95.3% and 78.3%, respectively [25]. These findings raised concern about possible role of PVF as a cause of measles outbreaks occurred in fully vaccinated individuals, possibly because of poor control of cold-chain and vaccination procedures, stunting and/or possible persistence of specific antibody beyond 12 months of age [15, 16, 24, 26, 27].

This study was designed to investigate the seroconversion rates of the MMR vaccine currently in use among a cohort of more than 12 month-old children following 2 doses of MMR vaccine given at the ages of 12 and 18 months. Also, the seroprevalence rates of specific immunity to MMR agents among children just before their immunization and its possible effects on the vaccine immunogenicity were determined.

| Author/reported province | Years of outbreaks | No of cases | Involved age groups | Vaccination status |
|--------------------------|-------------------|-------------|---------------------|-------------------|
| Nejati et al. [14]       | 2006–11           | 456 cases   | All age groups:     | One dose: 11.2%   |
|                         |                   |             | 48% in < 5 yrs      | 2-dose: 27.8%, not vaccinated: 55.1% |
|                         |                   |             | 34% in 5–9 yrs      |                   |
| Izadi et al. [15]        | 2009–10           | 126 cases   | All age groups:     | 2-doses vaccine efficacy: 74.2% |
|                         |                   |             | 42% ≥ 7 yrs         |                   |
|                         |                   |             | 6.3% > 20 yrs       |                   |
| Moghaddam et al. [16]    | 2012              | 7 cases     | 11 months–35 yr    | 2-cases: unknown  |
|                         |                   |             |                    | 3 cases full vaccinated |
|                         |                   |             |                    | 2 cases Non-vaccinated |
| Karami et al. [17]       | 2012 and 2014     | 2012: 232 cases | All age groups | 22.7% < 12 mo    |
|                         |                   | 2014: 142 cases |                    | 19.3% vaccinated  |
|                         |                   |             |                    | 36.5% non-vaccinated |
| Piri et al. [18], National level | 2014–2016 | 759 cases | 31.1% < 1 yr       | < 1 yr: 0.9% vaccinated |
|                         |                   |             | 13.2% 1–4 y        | 1–4 yr: 9% vaccinated |
|                         |                   |             | 11.6% 5–9 y        | 5–9 yr: 7.1% vaccinated |
|                         |                   |             |                    | 23.3% vaccinated   |

2–14 years after the national MR immunization program of 5–25 years-old population and the onset of two-dose MMR immunization program of ≥ 12 months old children in the country
Methods and subjects
Over a 22-month study period (1 October 2017 to 31 July 2019), healthy children aged ≥12 month-old who were brought to the primary health care centers for scheduled MMR immunization program in East of Mazandaran province, North of Iran were recruited on a voluntary basis. Children with acute illness, those with history of chronic diseases, or malignancies/ immunodeficiency, history of febrile exanthematous diseases or recipients of blood/ blood products/additional MMR or any measles containing vaccines, those with history of prematurity (gestational age <36 weeks and/or birth weight <2500 g), and any contraindications to MMR vaccination were excluded. Standard ethical guidelines and protocols were used and the study was approved by the Ethic Committee of the Mazandaran University of Medical Sciences; IR. MAZUM.REC1390.3073. After obtaining informed written consent from guardian, 3 ml (ml) blood was obtained from each infant- mother pair. Four- to 6 weeks after vaccination with MMR vaccine (MMR1); [Domestic Razi institute of serum and vaccines: Karaj- Iran (Measles: AIK- C, Mumps: Hoshino, Rubella: Takahashi all CCID50 1000), or MMR vaccine: Serum Institute of India: (Measles: Edmonston- Zagreb; CCID50 1000, Mumps; Leningrad- Zagreb CCID50 5000; Rubella wistar RA27/5 CCID50: 1000)], 3 ml of venous blood was collected from vaccinated infants. Vaccines were dispensed into multidose (2, 5 dose/vial) and were stored at −20 °C and reconstituted before vaccination. Reconstituted unused vaccines were discarded after 6 h. Collected sera were stored at −20 °C. Based on the objectives of the study, no intervention was done during vaccination procedures by researchers. According to the National Immunization program in Iran, these children came back for scheduled second dose of MMR vaccine (MMR2) after 6 months. 4 to 6 weeks after MMR2, third venous blood samples were obtained. All collected sera (mother and infant pairs) were tested for specific immunoglobulin G (IgG) against measles, mumps and rubella with ELISA methods, using semi quantitative Vircell microbiologist (measles IgG/ IgM, G/M 1001, mumps IgG/IgM, G/M 1014, and Rubella IgG, G/ 1026) ELISA Kits (Vircell, S.L. Parquet Tecnologico dela salud. Avequina 8.10.016 Granada, Spain), in the University laboratory.

Based on the manufacturer’s instructions the results were interpreted as antibody index. The antibody indices were calculated with positive and negative controls (OD >0.9 and OD <0.5) at a control cut-off range of >0.55 to <1.5. Antibody indices were measured as: (sample OD/ cut-off serum mean OD) ×10. Samples with antibody indices <9 were considered as negative (not containing protective titers of specific antibody), 9–11 equivocal and >11 as positive (seroprotected and immune). Equivocal samples were rechecked, and if <11, called as negative and if >11, interpreted as positive. This categorization was applied for three MMR agents. The rubella ELISA has been standardized against WHO first international standard for anti-Rubella IgG with a cut-off set at 10 IU/ml. The seroconversion rates against each agent among mother-infant pairs were calculated before vaccination. After MMR1, the proportion of responders and the mean concentration of antibodies (MCAs) for each agent were determined among seroconverted children. Also in order to determine the possible influence of maternal antibodies, immunologic responses to MMR1 vaccination and the proportion of responders and the acquired MCA levels, were compared between two groups of children including those with seropositive mothers and those without such history. Then, the proportion of seroconverted subjects among nonresponders to MMR1 and the MCA levels of both new responders and seroimmune subjects were calculated following MMR2 vaccination. Collected data were analyzed using SPSS version of 16.0. The descriptive statistical method was used in the form of percentile for seroconversion and response rate, and Chi-Square and students T-test were applied to find differences between variables as appropriate. Results were considered to be statistically significant when the P value was less than 0.05.

Results
For this study, during 22 months of study period, 92 mother- infant pairs were participated. Of 92 infants, 43 were females and 49 males; the mean age of mothers was 27.4 years (age range 21–42 years) and the mean age of mothers and infants was 27.4 years (age range 21–42 years) and the mean age of infants was 27.4 years (age range 21–42 years) and the mean age of children for MMR1 and MMR2 vaccination was 12.1 and 18.3 months, respectively. After the MMR1 vaccination, out of 92 participated children, 52 (56.5%) were willing to continue the study and blood samples were taken from them. Also, after MMR2 vaccination, 39 (42.4%) participants agreed to give blood samples. As are presented in Table 2, approximately, 85.8%, 84.7% and 86.9% of mothers and infants were immune against MMR agents. These rates were 3.2%, 2.1%, and 1.0%, respectively for children just before the first dose of MMR injection.

After administration of MMR1 vaccine, nearly 84.6%, 82.7% and 78.8% of seronegative vaccinated children responded to MMR agents of vaccine and became IgG seroconverted. None of the infants who were seropositive before MMR1 vaccination, were included in the further stages of study. The MCAs levels for three MMR agents were 22.20±6.35, 18.40±5.15 and 21.30±5.76, respectively. When these rates were compared between two groups of children (those born from seropositive mothers and those without this history), despite small sample size and lack of adequate power, no statistically significant
increased rate of seroconversion or MCA levels was identified in children of seronegative mothers (Table 3). After the MMR2 injection, of 39 studied children, 6 were susceptible to measles and 4 subjects responded to MMR2 and the total number of seroconverted children against measles reached to 37/39 (94.8%). These rates were 7 and 3 (35/39; 89.7%), 10 and 8 (37/39; 94.8%) for mumps and rubella respectively. The acquired MCAs levels were significantly higher than those after MMR1, indicating enhancement of immunity. MCA was, 28.44 ± 6.17 VS 22.20 ± 6.35 P = 0.003 for measles, 26.67 ± 5.80 VS 18.40 ± 5.15, P < 0.001 for mumps, and 27.08 ± 7.68 VS 21.30 ± 5.76, P = < 0.001 for rubella. All of these collected data are presented in Table 2.

Table 2 Anti‑Measles‑ Mumps‑ Rubella seroprevalence profiles among studied mother‑infant pairs just before MMR immunization, seroconversion rates and mean concentration of antibody levels following first and second dose of MMR vaccine given at the ages 12 and 18 months, Sari‑Iran 2018

| MMR vaccination status | Measles: n (%) | MCA ± SD | Mumps: n (%) | MCA ± SD | Rubella: n (%) | MCA ± SD |
|------------------------|---------------|----------|--------------|----------|----------------|----------|
| Pre‑MMR1 vaccination   |               |          |              |          |                |          |
| Mothers n = 92         | 79 (85.8%)    | 22.40 ± 7.25 | 78 (84.7%)  | 21.30 ± 5.76 | 80 (86.9%) | 19.18 ± 4.32 |
| Infants n = 92         | 3 (3.2%)      | –        | 2 (2.1%)     | –        | 1 (1.0%)     | –        |
| Post MMR1, n = 52      | 44 (48.6%)    | 22.20 ± 6.35 | 43 (82.7%)  | 18.40 ± 5.15 | 41 (78.8%) | 21.30 ± 5.76 |
| Post MMR2, n = 39      | 37 (94.8%)    | 28.44 ± 6.17 | 35 (89.7%)  | 26.67 ± 5.80 | 37 (94.8%) | 27.08 ± 7.68 |
| No of responders /no of susceptible (%) | 4/6 (66.6%) | 3/7 (42.8%) | 8/10 (80%) |
| Comparison between post MMR1 and MMR2 MCA levels; P value | P = 0.003 | P < 0.001 | P < 0.001 |

Table 3 The patterns of infants' immune response to MMR1 immunization in relation to their mother specific antibody status

| Infant mother antibodies status prior to MMR1 injection | Antibody positive | Antibody negative | P value |
|--------------------------------------------------------|-------------------|-------------------|---------|
| Measles; N = 52                                        | 43                | 9                 |         |
| Response rate (%)                                      | 83.72%            | 88.88%            | 0.6     |
| MCA level                                              | 21.08 ± 5.75      | 23.25 ± 5.03      | 0.34    |
| Mumps; n = 52                                          | 43                | 9                 |         |
| Response rate (%)                                      | 81.81%            | 87.50%            | 0.8     |
| MCA level                                              | 17.78 ± 4.31      | 18.66 ± 5.21      | 0.58    |
| Rubella; n = 52                                        | 45                | 7                 |         |
| Response rate (%)                                      | 77.77%            | 85.7%             | 0.63    |
| MCA level                                              | 20.23 ± 6.37      | 22.33 ± 4.72      | 0.44    |

Discussion

In this study, nearly 85% of investigated mothers were serologically immune to MMR viruses. Few more than 12 month-old infants also showed seroprotection against these agents before their scheduled MMR1 vaccination. After administering the MMR1 to more than 12 month-old children, nearly 84, 6%, 82.7% and 78.8% of vaccinated children responded to three components of MMR1 vaccine, and were seroconverted, respectively. However, these rates, were higher in infants of seronegative mothers. Six months after the initial MMR immunization, most serosusceptible children showed immunologic response to MMR2 and serologically achieved protection to MMR agents. Also, their earlier acquired seroimmunity following the first dose of MMR vaccine injection was enhanced. Finally, following administering 2- doses of MMR vaccine to children after the age of 12 months, approximately 94.8%, 89.7% and 94.8% of vaccinees acquired seroprotection to measles, mumps, and rubella, respectively.

Based on this study findings, most participated mothers were seropositive against three agents of vaccine. In addition to history of measles immunization during childhood, majority of our studied mothers were reimmunized in the national program of MR campaign conducted at the December 2003 [12]. However, none of these mothers were immunized against mumps earlier and their seroimmunity against mumps is the results of natural infection. The high rates of seropositivity against measles and rubella may be due to positive impact of MR reimmunization performed 13 to15 years earlier or it could be the result of exposure to natural infection in the past. Similar results are reported among Iranian childbearing age women with the same age recently. In a nationwide seroprevalence study among Iranian girls at the verge of marriage whom were MR reimmunized 13–14 years earlier, results showed that 80.7% (70.3-to 89.5%) and 90.6% (81.2-to 95%) were immune to measles and rubella, respectively. There was a sharp difference between those who were MR vaccinated and those who were not. They concluded that these high rates of seroimmunity were the positive impact of MR revaccination [28].
these antibodies disappear during first few months of life, higher levels will persists for a longer time [29].

According to our data, using ELISA method for antibody measurement, a few children were seroimmune to MMR agents just before MMR vaccination. The exact origin of these antibodies is not clear, but most probably is maternal. In a similar study from the region among 112 mother-infant pairs in year 2008 (5-years after the national MR campaign), nearly 6.2% and 10.7% of 12 month-old infants, all from MR reimmunized mothers, retained their seroimmunity to measles and rubella, respectively [27]. Also, in another similar study from southeast of Iran, using ELISA method, nearly 3.7% of 12 month-old infants were serologically immune to measles just before MMR1 vaccination [26]. The point of concern is that ELISA method is not sensitive enough to detect low titers of measles antibodies [30]. Therefore, if a more sensitive method has been used, probably a higher proportion of infants would have shown specific immunity (retained their passive immunity) just before MMR1 immunization. Since MMR vaccine is a live attenuated vaccine, the presence of specific antibody may have a negative influence on the immunogenicity of the vaccine. This assumption was confirmed by studies conducted in the 1990s [31–33]. In a serological study, using a sensitive virus neutralization test, it was found that many 12 month-old children had preexisting maternal antibody to measles virus and their immunological response to measles vaccination was affected [31]. In this study, after giving scheduled MMR1 vaccine to more than 12 month-old seronegative children, nearly 15%, 17%, and 21%, of vaccinated children remained seronegative to MMR agents (PVF), respectively. When these results were compared between 2 groups of children, these rates were higher in children of seropositive mothers.

Other researchers have also investigated the immunogenicity of MMR vaccine among Iranian children older than 12 months [24–27]. Most of these studied results showed a lower than expected seroconversion rates, even after strict control of vaccination procedures and cold-chain regulation. The rates of PVF detected in Iranian studies were higher than the rates reported worldwide. The main possible reason for the higher rates of PVF observed in our study as well as other Iranian studies may be due to presence of low concentrations of specific antibodies, particularly anti-measles antibody, undetectable by ELISA method, and its negative influence on the immunogenicity of the MMR vaccine [31–33]. However, the possible negative impact of technical problems in vaccination procedure should be also considered [15, 16, 24–27]. Further studies are recommended to investigate the presence of specific antibodies, particularly anti-measles antibody by a more sensitive method just before MMR1 immunization at the age 12–13 months as well as its effects on the immunogenicity of MMR vaccine. Furthermore, periodic educational sessions are suggested for vaccinators to improve vaccination techniques, particularly cold-chain regulation.

After administering the MMR2 vaccine to 18 months old previously MMR1 vaccinated children, most susceptible ones were acceptably seroconverted. Also, their earlier acquired immunity was enhanced. However, the overall seroprotection rates detected in this study following 2-doses of MMR vaccine were lower than expected in the world. Results of most studies in the world indicates that vaccination with 2-doses of MMR vaccine after the age of 12 months is associated with >95–98% seroconversion rate [1, 8–11, 20–22], but the results of most studies reported from Iran are varied and show lower rates than the global results [19, 24, 34]. While the result of one study from north of Iran showed seroconversion rates of 98.2% and 94.4% for measles, 92.4% and 87% for rubella component after MMR2 vaccine given at the age of 6 years or 18 months [34], in another study from Ahwaz 6 months after MMR vaccination of 6.5 year-old children with history of 2-doses of Mmv at the ages of 9 and15 months, the seropositivity rate was 45.6%, for measles,76.7% for mumps and 87.7% for rubella [24]. However, our data in this study indicated acceptable, but not optimal seroconversion rates among Iranian children following two-doses of MMR immunization.

Considering these rates of seroprotection along with 97% vaccination coverage rate in all districts of the country, a population immunity rate of about 91.9%, 87.0% and 91.9% for MMR agents could be estimated, respectively. The concerning point is that vaccine-induced antibodies against measles and mumps decrease faster over time comparing to rubella [35–37]. Therefore, an increasing numbers of potentially measles-mumps susceptible population will accumulate in the community and facilitate outbreaks even among fully vaccinated subjects [38–40]. However, this rate of immunity against measles is lower than that is required in a community to eliminate/sustain measles elimination [1, 8–11]. The rates for mumps and rubella are at the lowest threshold to eliminate mumps and rubella epidemics [4, 8]. To prevent the measles virus transmission in a community, a population immunity rate of 93% to 95% with >95% two-dose vaccine coverage rate is required in all districts of the country. This level for rubella and mumps is estimated as 88% to 90% [8–11]. Therefore, these levels of immunity are challenging in mid- to long-term period and raise concern about the sustaining measles-rubella elimination in the country which has received certificate of elimination in the last 2 years [41]. While considering our data and other Iranian studies reports, periodic serosurveillance
are recommended to monitor population immunity against MMR. Further studies with larger sample size, using more sensitive laboratory methods to measure low levels of specific antibodies just before MMR1 immunization along with strict control of cold-chain regulation and vaccination procedures in primary health care and vaccination centers are suggested. If these results are confirmed by further studies, changing the age of the first dose of MMR vaccine to 14 to 15 months and/or considering additional universal dose of MMR vaccine at the older age are recommended.

The main limitations of this study include its small sample size and also using two brands of MMR vaccine interchangeably that may influence the final results.

Conclusion
Based on the study findings, the seroconversion rates detected following two-doses of the MMR vaccine currently in use in the country is acceptable in short-term. However, to maintain mid- to long-term herd immunity, national or regional supplementary immunization activities seem reasonable. Similar studies with larger sample size in different regions of the country are recommended to measure specific antibody concentration particularly measles antibody with a more sensitive method before first dose of MMR administration, and also consider strict control of cold-chain and vaccine administering techniques to assess the MMR vaccine immunogenicity.

Abbreviations
MMR: Measles mumps rubella; ELISA: Enzyme-linked immunosorbent assay; CRS: Congenital rubella syndrome; WHO: World health organization; PVF: Primary vaccine failure; SVF: Secondary vaccine failure; mMV: Monovalent measles vaccine; MAZUMS: Mazandaran University of Medical Sciences; IgG: Immunoglobulin G; MCA: Mean concentration antibodies; MR: Measles-rubella; ml: Milliliter; OD: Optical density.

Acknowledgements
The researchers would like to thanks the children and their parents for participation in this study, as well as the staff of primary health care centers for vaccinating children and providing information about vaccination procedures and mother-infant pairs. Also, we appreciate the staff in the provincial center vaccinating children and providing information about vaccination procedures in primary health care centers and vaccination procedures in primary health care centers and vaccination centers.

Authors’ contributions
HnS Involved in study design, literature search, laboratory testing and writing the paper. SJM data collection and statistical analysis and interpretation. HvS Involved in study design, literature search, laboratory testing and writing the paper. MP and GG involved in recruiting, interview and blood sampling. MAJS all phases of the study. All authors read and approved the final manuscript.

Funding
This study was funded by Vice–chancellor for research and Technology MAZUMS No: (IR, MAZUMS, Rec. 3082). The funder had no role in the design of the study and collection, analysis, interpretation of collected data and writing of manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethic approval and consent to participate
The study was provided ethical approval by the MAZUMS No: IR, MAZUMS, Rec. 3082. The study obtained the consent of all participants and signed and informed consent form prior to investigation. They were assured about confidentiality and that their contribution would be on a voluntary basis as well as that they had full rights to withdraw from the study at any time.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interest.

Author details
1 Department of Anatomical and Clinical Pathology, IKHC, Teheran University of Medical Sciences, Tehran, Iran. 2 Department of Community Medicine, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. 3 Department of Pathology, Shariati Hospital, Teheran University of Medical Sciences, Tehran, Iran. 4 Deputy of Health, Mazandaran University of Medical Sciences, Sari, Iran. 5 Pediatric Infectious Diseases Research Center, Communicable Diseases Institute and Department of Pediatric Infectious Diseases, Bu-Ali Sina Hospital, Mazandaran University of Medical Sciences, Pasdaran Blvd, Sari, Iran.

Received: 25 April 2021 Accepted: 10 November 2021
Published online: 16 January 2022

References
1. World Health Organization. Measles. WHO position paper. Wkly Epidemiol Rec. 2017;19(92):205–28.
2. World Health Organization. Measles. Key facts.5 Dec 2019. www.WHO.int/news-room/fact-sheet/detail/measles.
3. Center for Disease Control and Prevention (CDC). Global Health. Global measles outbreaks. www.cdc.gov/globalhealth/measles/globalmeaslesoutbreaks.html.
4. Lam E, Basen JB, Zucker JR. Mumps: an update on outbreaks, vaccine efficacy and Genomic diversity. Clin Microbiol Rev. 2020;33(2).
5. Center for Disease Control and Prevention (CDC). Mumps for Health-care providers. www.cdc.gov/mumps/hep.html.
6. Lambert N, Strebel P, Orenstein W, Kenigole J, Poland GA. Rubella. Lancet. 2015;385(9984):2297–307.
7. World Health Organization. Rubella. Key facts. 4 Oct 2019. www.WHO.int/news-room/fact-sheets/detail/Rubella.
8. Bankamp B, Hickman C, Kenigole JP, Rota PA. Successes and challenges for preventing measles, mumps and rubella by vaccination. Curr Opin Virol. 2019;34:110–6.
9. Holzmann H, Hengel H, Tenbusch M, Doer Hw. Eradication of measles: remaining challenges. Med Microbiol Immunol. 2016;205(3):201–8.
10. Orenstein WA, Cairns L, Hinman A, Nikoware B, Olvé JM, et al. Measles and Rubella Global Strategic Plan 2012–2020 midterm review report: background and summary. Vaccine. 2018;36(Suppl 1):A35–42.
11. Hinman AR. Measles and rubella eradication. Vaccine. 2018;36(1):1–3.
12. Zahraei SM, Gouya MM, Azad TM, Soltanmshahi R, Sabouri A, et al. Successful control and impending elimination of measles in the Islamic Republic of Iran. J Infect Dis. 2011;204(Suppl 1):S305–11.
13. Telbê N, Lebo E, Ahmed H, Hossam AR, El Sayed El, et al. Progress toward measles elimination Eastern Mediterranean Region, 2008–2012. MMWR Morb Mortal Wkly Rep. 2014;63(23):511–5.
14. Nejati J, Sargolzaei N, Kiani M, Mahjoob M, Hashemi A. Measles epidemiology in Sistan and Baluchestan Province during April 2006–March 2011. Health Scope. 2013;2(1):58–62.
15. Izadi S, Zahrane SM, Sartipi M. An investigation into a measles outbreak in southeast Iran. Jpn J Infect Dis. 2012;65(1):45–51.
16. Moghadam M, Afsarkazerooni P, Ebrahimi M, Soltani M, Razmaoar A, et al. Measles outbreak in South of Iran, where vaccine coverage was high: a case-series study. Iran J Public Health. 2014;43(5):375–80.
17. Karami M, Zahraei SM, Sabouri A, Soltanashahi R, Biderash A, et al. Documentation of measles elimination in Iran: evidences from 2012 to 2014. J Res Health Sci. 2017;17(3):e00387.
18. Piri N, Karami M, Tapak L, Zahraei SM, Mohammadi Y. Monitoring progress towards the elimination of measles in Iran: supporting evidence from 2014 to 2016 by application of measles outbreaks data. BMC Public Health. 2019;19(1):667.
19. Izadi S, Mokhtari-Azad T, Zahraei SM. Measles vaccination coverage and seroreversal of anti-measles antibody in south-east Islamic Republic of Iran. East Mediterr Health J. 2015;21(6):396–402.
20. Carazo S, Billard MN, Boutil A, De Serres G. Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):251.
21. Perez SC, De Serres G, Bureau A, Skovronski DM. Reduced antibody response to infant measles vaccination: effects based on type and timing of the first vaccine dose persist after the second dose. Clin Infect Dis. 2017;65(7):1094–102.
22. Redd SC, King GE, Heath JL, Forghani B, Bellini WI, et al. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis. 2004;189(Suppl 1):S16–22.
23. Saffar H, Saffar MJ, Saffar H. Vaccination in developing countries: a review of probable factors for lower responses to vaccines. J Pediatr Rev. 2013;1(1):12–8.
24. Shamsizadeh A, Nikfar R, Mavandi M, Hakimzadeh M, Alisamir, et al. Seroprevalence of measles, mumps and rubella Antibodies in 18 months and 6.5 years old children: 6 months after measles-mumps-rubella (MMR) vaccination. Jundishapur J Microbiol. 2012;5(4):578–81.
25. Rafie Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, et al. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children. Arch Iran Med. 2013;16(1):38–41.
26. Zahraei SM, Izadi S, Mokhtari-Azad T. Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. Hum Vaccin Immunother. 2016;12(13):3118–24.
27. Saffar MJ, Ajami A, Khalilian AR, Saffar H. The impact of maternal measles-rubella immunization on the 12-month-old infant’s immune response to measles-mumps-rubella vaccine immunogenicity. Eur J Clin Microbiol Infect Dis. 2009;28(7):845–7.
28. Zahraei SM, Mokhtari-Azad T, Izadi Sh, Mohammad M, Sabouri A. Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. Vaccine. 2020;38(2):235–41.
29. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. 2007;25(34):6296–304.
30. Ratnam S, Gadag V, West R, Burns J, Oates E, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol. 1995;33(4):811–5.
31. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1997;91(5):715–8.
32. Stewren KE, Barbosa V, de Lima OS, Osoro K. The influence of maternally derived antibody on the efficacy of further attenuated measles vaccine. Infection. 1978;6(5):207–10.
33. Johnson CE, Darbari A, Darbari DS, Nalin D, Whitwell J, Chui LW, Cleves MA, Kumar ML. Measles vaccine immunogenicity and antibody persistence in 12 vs 15-month-old infants. Vaccine. 2000;18(22):2411–5.
34. Saffar MJ, Fatipour GR, Parsaei MR, Ajami A, Khalilian AR, et al. Measles-mumps-rubella revaccination, 18 months vs. 4–6 years of age: potential impacts of schedule changes. J Trop Pediatr. 2011;57(5):347–51.
35. Smetana J, Chlibek R, Hanovcova I, Sosvickova R, Smetanova L, et al. Decreasing seroconversion of measles antibodies after vaccination—possible gap in measles protection in adults in the Czech Republic. PLoS ONE. 2017;12(1):e0170257.
36. Kang HJ, Han YW, Kim SJ, Kim YJ, Kim AR, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine. 2017;35(33):4126–32.